Patents Assigned to The United States of America as represented by the Secretary, Dept. of Health and Human Services
  • Publication number: 20210253655
    Abstract: Some embodiments of the invention include polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include nucleic acid molecules encoding polypeptides comprising a myomerger polypeptide or an extracellular myomerger polypeptide. Other embodiments of the invention include vectors comprising the nucleic acid molecule. Yet other embodiments of the invention include methods of using a myomerger polypeptide or an extracellular myomerger polypeptide. Additional embodiments of the invention are also discussed herein.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 19, 2021
    Applicants: CHILDREN'S HOSPITAL MEDICAL CENTER, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Douglas MILLAY, Dilani GAMAGE, Leonid CHERNOMORDIK, Evgenia LEIKINA
  • Patent number: 11078239
    Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: August 3, 2021
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
  • Publication number: 20210214751
    Abstract: Disclosed herein are codon-optimized nucleic acids encoding a reduced-size ATP7A protein. Also disclosed are vectors and recombinant viruses (such as recombinant adeno-associated viruses) including the codon-optimized nucleic acids encoding the reduced-size ATP7A protein and compositions including the disclosed vectors and viruses. Further disclosed herein are methods of treating copper transport disorders, for example by administering a disclosed nucleic acid, vector, or recombinant virus to a subject with a copper transport disorder, such as Menkes disease, occipital horn syndrome, or ATP7A-related distal motor neuropathy.
    Type: Application
    Filed: March 30, 2021
    Publication date: July 15, 2021
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventor: Stephen G. Kaler
  • Patent number: 11051902
    Abstract: A system for planning and performing a repeat interventional procedure includes a registration device (116) and an image generation device (120) which map current targets in a reference image (104) for a first interventional procedure to at least one guidance image (112) acquired from a different imaging modality. Biopsy locations are recorded to the guidance images during the first interventional procedure and the biopsy locations are mapped to the reference image to provide a planning image for use in a subsequent interventional procedure on the patient. In a subsequent interventional procedure, the prior planning image (124) may be registered to a current reference image (126) and the prior biopsy locations and prior and current targets are mapped to a guidance image acquired from a different imaging modality. Biopsy locations are then mapped to the guidance image (115) and mapped back to the current reference image.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 6, 2021
    Assignees: KONINKLIJKE PHILIPS N.V., THE UNITED STATES OF AMERICA, as represented by the SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES
    Inventors: Jochen Kruecker, Pingkun Yan, Amir Mohammad Tahmasebi Maraghoosh, Peter A Pinto, Bradford Johns Wood
  • Patent number: 11052057
    Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: July 6, 2021
    Assignees: MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Dept of Health and Human Services
    Inventors: Benjamin Rubin, Raj Puri, Bharat Joshi
  • Publication number: 20210177967
    Abstract: The disclosure provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The disclosure also features kits for carrying out the methods.
    Type: Application
    Filed: February 4, 2021
    Publication date: June 17, 2021
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Wan Jun Chen, Shimpei Kasagi, Pin Zhang
  • Patent number: 11026947
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: June 8, 2021
    Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept, of Health and Human Services
    Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
  • Publication number: 20210069317
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
    Type: Application
    Filed: November 19, 2020
    Publication date: March 11, 2021
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Publication number: 20210010001
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 14, 2021
    Applicants: Sarepta Therapeutics, Inc., The Progeria Research Foundation, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, University of Maryland, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • Publication number: 20200399318
    Abstract: Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The University of Tokyo, New England Biolabs, Inc.
    Inventors: James Inglese, Patricia Dranchak, Ryan MacArthur, Hiroaki Suga, Hao Yu, Clotilde Carlow, Zhiru Li
  • Publication number: 20200392469
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 17, 2020
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • Publication number: 20200392457
    Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.
    Type: Application
    Filed: November 1, 2018
    Publication date: December 17, 2020
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard W. Childs, David S.J. Allan
  • Publication number: 20200360436
    Abstract: Disclosed herein are modified NK cells, compositions comprising modified NK cells, and methods for treating a tumor or hyperproliferative disease in a subject. In some embodiments, the modified NK cells include NK cells including a heterologous nucleic acid molecule encoding a CD16 protein comprising a valine at amino acid position 158 (CD16-V158), a heterologous nucleic acid molecule encoding a CCR7 protein, or both. In some embodiments, methods include treating a subject with a tumor by administering a composition comprising an anti-cancer monoclonal antibody and administering a composition comprising the modified NK cells to the subject. Also disclosed are methods of making modified NK cells by obtaining a population of NK cells from a subject and transfecting the population of NK cells with a heterologous nucleic acid molecule encoding CD16-V158, a heterologous nucleic acid molecule encoding a CCR7 protein, or both.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Richard W. Childs, Mattias C.V. Carlsten
  • Patent number: 10822608
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 3, 2020
    Assignees: Sarepta Therapeutics, Inc., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, University of Maryland, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • Publication number: 20200334558
    Abstract: Methods include compressing a plurality of time domain samples with a processor and memory by providing the plurality time domain samples and a plurality of power bins, identifying an activity window corresponding to a sequence of the time domain samples that are above a selected power threshold, determining a power average for the activity window, assigning the power average to one of the power bins having a range that includes the power average, and storing the assigned power bin and number of time domain samples of the activity window. Related decompression methods that can estimate a radio frequency power over time from the compressed power window data, as well as systems employing compression and/or decompression methods are also disclosed. Selected examples employ Gaussian mixture models and Bayesian responsibility functions.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 22, 2020
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Mohamad Omar Al Kalaa, Seth J. Seidman
  • Patent number: 10767184
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 8, 2020
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20200233051
    Abstract: An approach is presented to reconstruct image data for an object using a partial set of magnetic resonance (MR) measurements. A subset of data points in a data space representing an object are selected (e.g. through random sampling) for MR data acquisition. Partial MR data corresponding to the subset of data points is received and used for image reconstruction. The overall speed of image reconstruction can be reduced dramatically by relying on acquisition of data for the subset of data points rather than for all data points in the data space representing the object. Compressive sensing type arguments are used to fill in missing measurements, using a priori knowledge of the structure of the data. A compressed data matrix can be recovered from measurements that form a tight frame. It can be established that these measurements satisfy the restricted isometry property (RIP). The zeroth-order regularization minimization problem can then be solved, for example, using a 2D ILT approach.
    Type: Application
    Filed: April 3, 2020
    Publication date: July 23, 2020
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, University of Maryland, College Park
    Inventors: Peter J. Basser, Ruiliang Bai, Alexander Cloninger, Wojciech Czaja
  • Publication number: 20200197420
    Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.
    Type: Application
    Filed: March 3, 2020
    Publication date: June 25, 2020
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
  • Publication number: 20200147010
    Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.
    Type: Application
    Filed: October 7, 2019
    Publication date: May 14, 2020
    Applicants: MESHABERASE, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Benjamin RUBIN, Raj PURI, Bharat JOSHI
  • Publication number: 20200147202
    Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.
    Type: Application
    Filed: January 23, 2020
    Publication date: May 14, 2020
    Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human Services
    Inventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy